News >

Time Between Neoadjuvant and Adjuvant Chemo Impacts OS in Ovarian Cancer

Jason Harris
Published: Monday, Dec 04, 2017

Patients with ovarian cancer who begin postoperative adjuvant chemotherapy within 42 days of ending neoadjuvant chemotherapy have superior survival compared to those who initiate therapy after that point.

for trend <.001). Patients in the highest quartile (>50 days) had the highest risks of recurrence (HR, 1.93; 95% CI, 1.16-3.20) and death (HR, 2.06; 95% CI, 1.05-4.02), as compared with patients in the lowest quartile (≤37 days).
Lee YJ, Chung YS, Lee J, et al. Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer [published online November 21, 2017]. Gynecol Oncol doi: 10.1016/j.ygyno.2017.11.023.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Community Practice Connections™: Advances in Ovarian Cancer: Evolving Applications for PARP Inhibitors, Immunotherapy & Beyond!Aug 30, 20201.5
Publication Bottom Border
Border Publication
x